Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000352

Purpose

The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Dextromethorphan	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients

Resource links provided by NLM:

Drug Information available for: Dextromethorphan hydrochloride Methadone Levomethorphan Dextromethorphan Racemethorphan Dextromethorphan hydrobromide

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:	0
Study Start Date:	December 1996

Eligibility

Ages Eligible for Study:	21 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000352

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

No publications provided

Study ID Numbers:	NIDA-3-0012-1, Y01-3-0012-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000352 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Respiratory System Agents
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Disorders of Environmental Origin
Excitatory Amino Acid Agents
Opioid-Related Disorders
Pharmacologic Actions

Pathologic Processes
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Dextromethorphan
Antitussive Agents
Central Nervous System Agents
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on February 08, 2010